Palantir, Square, Genius Sports, Zymergen — Stocks Cathie Wood’s Ark Bought Or Sold Thursday
Cathie Wood-led Ark Invest continues to pile up shares in Palantir Technologies Inc (NYSE: PLTR).
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Aug. 18, 2021: PATH, PLTR, Z, RPTX, SURF, QSI, VCYT, PFE, NVTA, ZY, MASS, EXAS, DYNS, CRSP, SMFR, TSP, SRNG, SGFY, NTLA, BEAM, FATE, EDIT, AVAV, BLDE, KMTUY, MKFG, CND, GENI, KVSB, LPSN
UiPath (PATH) - 80,400 Shares
Palantir Technologies (PLTR) - 93,189
Zillow Group (Z) - 21,507
Repare Therapeutics (RPTX) - 3,791
Surface Oncology (SURF) - 41,741
Quantum-Si (QSI) - 130,116
Veracyte (VCYT) -
Cathie Wood’s ARK Invest Posts Fund Purchases For Tuesday, Aug. 17, 2021: PLTR, Z, RPTX, VCYT, QSI, ZY, NTLA, MASS, EDIT, DYNS, CRSP, BLI, SMFR, FATE, EXAS, SGFY, BEAM, NVTA, AVAV, MKFG, BLDE, KMTUY, RBLX, LPSN, KVSB, CND
Palantir Technologies (PLTR) - 476,114 Shares
Zillow Group (Z) - 2,800
Repare Therapeutics (RPTX) - 8,967
Veracyte (VCYT) - 40,152
Quantum-Si (QSI) - 163,972
Zymergen (ZY) - 136,853
Intellia Therapeutics (NTLA) -
Cathie Wood’s ARK Invest Posts Fund Purchases For Friday, Aug. 13, 2021: DKNG, BEAM, ZY, SMFR, BLI, TSP, SGFY, PLTR, AVAV, MKFG, VUZI, LPSN
DraftKings (DKNG) - 10,996
Beam Therapeutics (BEAM) - 13,452
Zymergen (ZY) - 96,945
Sema 4 Holdings (SMFR) - 1,816,927
Berkeley Lights (BLI) - 70,152
TuSimple Holdings
Cathie Wood’s ARK Invest Posts Fund Purchases For Thursday, Aug. 12, 2021: DKNG, ETSY, PLTR, SMFR, ZY, CRSP, SDGR, VCYT, TSP, SGFY, BLI, VUZI, MKFG, LPSN
DraftKings (DKNG) - 55,100 Shares
Etsy (ETSY) - 27,834
Palantir Technologies (PLTR) - 5,602,325
Sema4 (SMFR) - 183,204
Zymergen (ZY) - 8,322
CRISPR Therapeutics (CRSP) - 25,000
Schrodinger (SDGR) -
Analyzing Zymergen’s Unusual Options Activity
On Monday, shares of Zymergen (NASDAQ:ZY) saw unusual options activity. After the option alert, the stock price moved down to $11.98.
Zymergen Holds ‘Deep Intrinsic Value’ Despite Wobbly Short-Term Outlook, Says Cathie Wood’s Ark
Cathie Wood-led Ark Invest said on Friday it continues to believe Zymergen Inc (NASDAQ: ZY)’s platform holds deep intrinsic value despite the recent setback and a lowered short-term outlook.
